Volume 9, Number 12—December 2003

Dispatch

Visceral Leishmaniasis Treatment, Italy

Luigi Gradoni* , Marina Gramiccia*, and Aldo Scalone*

Author affiliations: *Istituto Superiore di Sanità, Rome, Italy

Main Article

Figure 2

Figure 2. Annual proportion of immunocompetent patients with visceral leishmaniasis treated with meglumine antimoniate (MA) or amphotericin B (AmB) in the period 1995–2001.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.